Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins

Johannes Winkler, Patricia Martin-Killias, Andreas Plückthun and Uwe Zangemeister-Wittke
Johannes Winkler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Martin-Killias
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Plückthun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Zangemeister-Wittke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0402 Published September 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: September 2009 to February 2021

AbstractFull-text HTMLPDF
Total318832001948

Cited By

Article Information

Volume 8, Issue 9, pp. 2674-2683

DOI 
https://doi.org/10.1158/1535-7163.MCT-09-0402
PubMed 
19723880

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received May 8, 2008
  • Revision received July 23, 2009
  • Accepted July 27, 2009
  • Published first September 1, 2009.

Article Versions

  • Previous version (September 1, 2009 - 08:45).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2009 American Association for Cancer Research.

Author Information

  1. Johannes Winkler1,3,
  2. Patricia Martin-Killias2,
  3. Andreas Plückthun2 and
  4. Uwe Zangemeister-Wittke1,2
  1. 1Institute of Pharmacology, University of Bern, Bern, Switzerland; 2Department of Biochemistry, University of Zürich, Zürich, Switzerland; and 3Department of Medicinal Chemistry, University of Vienna, Vienna, Austria
  1. Requests for reprints:
    Uwe Zangemeister-Wittke, Institute of Pharmacology, University of Bern, Friedbühlstrasse 49, 3010 Bern, Switzerland. Phone: 41-31-632-3290; Fax: 011-41-31-632-4229. E-mail: uwe.zangemeister{at}pki.unibe.ch
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (9)
September 2009
Volume 8, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
Johannes Winkler, Patricia Martin-Killias, Andreas Plückthun and Uwe Zangemeister-Wittke
Mol Cancer Ther September 1 2009 (8) (9) 2674-2683; DOI: 10.1158/1535-7163.MCT-09-0402

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
Johannes Winkler, Patricia Martin-Killias, Andreas Plückthun and Uwe Zangemeister-Wittke
Mol Cancer Ther September 1 2009 (8) (9) 2674-2683; DOI: 10.1158/1535-7163.MCT-09-0402
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Mcl-1 Determines the Fate of KSP-Inhibited Cells
  • PX-478 Radiosensitization in Pancreatic Cancer
  • Metronomic Gemcitabine Inhibits Pancreatic Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement